Cutaneous malignant melanoma mortality in Spain from 1979 to 2018. Trends and new perspectives in the immunotherapy era.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
15
05
2020
accepted:
22
09
2020
pubmed:
9
10
2020
medline:
15
5
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
Recent studies suggest that cutaneous melanoma mortality rates in Spain are stabilizing and even decreasing in younger cohorts. To analyse mortality rates of melanoma from the last 40 years, focusing on changes related with the development of new therapeutic approaches. Death records and mid-year population data were collected from the National Statistics Institute. By using the direct method, age-standardized mortality rates were calculated for overall population and for each sex and age group. Significant changes in mortality trends were identified by Joinpoint regressions. The independent effects of age, period and cohort (APC) and potential years of life lost (PYLL) due to melanoma were also analysed. Age-standardized melanoma mortality rates rose in Spain from 0.78 to 2.13 deaths per 100 000 from the first to the last quinquennium of the study (1979-1983 to 2014-2018) for the overall population. After a marked increase until 1995, mortality rates levelled off. Following this stabilization, from 2015 to 2018 there was a decrease in mortality rates for the overall population (average annual per cent change (AAPC): -4.3, not significant), more accused in males over 64 years old (yo). A period effect was observed from the beginning of 21st century, with mortality rates dropping to date. There is a decrease in melanoma mortality rates from 2015 in all age groups that confirms previous trends in mortality in younger cohorts. Improvement in diagnosis and development of new therapies for advanced melanoma may have a crucial role in this event. Close monitoring of melanoma mortality rates is necessary to confirm these trends.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies suggest that cutaneous melanoma mortality rates in Spain are stabilizing and even decreasing in younger cohorts.
OBJECTIVES
OBJECTIVE
To analyse mortality rates of melanoma from the last 40 years, focusing on changes related with the development of new therapeutic approaches.
METHODS
METHODS
Death records and mid-year population data were collected from the National Statistics Institute. By using the direct method, age-standardized mortality rates were calculated for overall population and for each sex and age group. Significant changes in mortality trends were identified by Joinpoint regressions. The independent effects of age, period and cohort (APC) and potential years of life lost (PYLL) due to melanoma were also analysed.
RESULTS
RESULTS
Age-standardized melanoma mortality rates rose in Spain from 0.78 to 2.13 deaths per 100 000 from the first to the last quinquennium of the study (1979-1983 to 2014-2018) for the overall population. After a marked increase until 1995, mortality rates levelled off. Following this stabilization, from 2015 to 2018 there was a decrease in mortality rates for the overall population (average annual per cent change (AAPC): -4.3, not significant), more accused in males over 64 years old (yo). A period effect was observed from the beginning of 21st century, with mortality rates dropping to date.
CONCLUSIONS
CONCLUSIONS
There is a decrease in melanoma mortality rates from 2015 in all age groups that confirms previous trends in mortality in younger cohorts. Improvement in diagnosis and development of new therapies for advanced melanoma may have a crucial role in this event. Close monitoring of melanoma mortality rates is necessary to confirm these trends.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
884-891Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Cancer.org [Internet]. Atlanta GACS c2020 [cited 2020 A 23]. URL https://www.cancer.org/es/cancer/cancer-de-piel-tipo-melanoma/acerca/estadisticas-clave.html (last accessed 23 April 2020).
Global Cancer Observatory [Internet]. Lyon FIA for R on CWHO c2018-20 [cited 2020 A 23]. URL http://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900 (last accessed 23 April 2020).
Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-387.
Gutiérrez-González E, López-Abente G, Aragonés N et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982-2016): sex-specific age-cohort-period effects. J Eur Acad Dermatology Venereol 2019; 33: 1522-1528.
Erdmann F, Lortet-Tieulent J, Schüz J et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Cancer 2007; 110: 2614-2627.
Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Madrid S c2017 [cited 2020/08/08]. URL https://cima.aemps.es/cima/publico/home.htm (last accessed 8 August 2020).
BIFIMED: Buscador de la Información sobre la situación de financiación de los medicamentos. Ministerio de Sanidad, Consumo y Bienestar Social [Internet]. [cited 2020/08/08]. URL https://www.mscbs.gob.es/profesionales/medicamentos.do? (last accessed 8 August 2020).
Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
Robert C, Soria J-C, Eggermont AMM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49: 2968-2971.
Cayuela A, Rodriguez-Dominguez S, Lapetra-Peralta J, Conejo-Mir JS. Has mortality from malignant melanoma stopped rising in Spain? Analysis of trends between 1975 and 2001. Br J Dermatol 2005; 152: 997-1000.
Cayuela A, Rodríguez-Domínguez S, Vigil E, Conejo-Mir JS. Effect of age, birth cohort and period of death on skin melanoma mortality in Spain, 1975 through 2004. Int J Cancer 2008; 122: 905-908.
Cayuela A, Cayuela L, Rodríguez-Domínguez S et al. Is melanoma mortality declining in Spain? Analysis of trends from 1975 to 2016. Br J Dermatol 2018; 179: 991-992.
Pace M, Cayotte EAL et al. Revision of the European Standard Population: report of Eurostat’s task force : 2013 edition. [Internet]. Publications Office, Luxembourg, 2013. [cited 2018 May 7]. URL http://dx.publications.europa.eu/10.2785/11470. doi: 10.2785/11470
National Cancer Institute. Joinpoint regression program, version 4.2.0.2, statistical methodology and applications branch, surveillance research program, national cancer institute 2015. No Title.
Decarli A, La Vecchia C, Malvezzi M, Micciolo R. An R package for fitting age, period and cohort models. Epidemiol Biostat Public Heal 2014; 11:e9977-1-12.
Osmond C, Gardner MJ. Age, period and cohort models applied to cancer mortality rates. Stat Med 1982; 1: 245-259.
Sáenz S, Conejo-Mir J, Cayuela A. Epidemiología del melanoma en España. Actas Dermosifiliogr 2005; 96: 411-418.
Arnold M, Holterhues C, Hollestein LM et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatology Venereol 2014; 28: 1170-1178.
Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM et al. Cancer incidence and mortality in spain: a systematic review and meta-analysis. Actas Dermosifiliogr 2016; 107: 318-328.
Crocetti E, Mallone S, Robsahm TE et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2179-2190.
Galceran J, Uhry Z, Marcos-Gragera R, Borràs J. Trends in net survival from skin malignant melanoma in six European Latin countries. Eur J Cancer Prev 2017; 26: S77-S84.
Sánchez C-M. Campañas de prevención del melanoma. Piel 2002; 17: 457-465.
Conejo-Mir J, Bravo J, Díaz-Pérez JL et al. Euromelanoma day. Results of the 2000, 2001 and 2002 campaigns in Spain. Actas Dermosifiliogr 2005; 96: 217-221.
MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-591.
Giblin A-V, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthetic Surg 2007; 60: 32-40.
Aceituno-Madera P, Buendía-Eisman A, Arias-Santiago S, Serrano-Ortega S. Changes in the incidence of skin cancer between 1978 and 2002. Actas Dermosifiliogr 2010; 101: 39-46.
Sattar J, Kartolo A, Hopman WM et al. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. J Geriatr Oncol 2019; 10: 411-414.
Joshi K, Atwal D, Ravilla R et al. Immunotherapy outcomes in advanced melanoma in relation to age. Perm J 2020; 24. https://doi.org/10.7812/TPP/19.093
Duma N, Abdel-Ghani A, Yadav S et al. Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal? Oncologist 2019; 24: e1148-e1155.
Wallis CJD, Butaney M, Satkunasivam R et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers. JAMA Oncol 2019; 5: 529.
Berk-Krauss J, Stein JA, Weber J et al. New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986-2016. Am J Public Health 2020; 110: 731-733.
Yang DD, Salciccioli JD, Marshall DC et al. Trends in malignant melanoma mortality in 31 countries from 1985 to 2015. Br J Dermatol 2020. https://doi.org/10.1111/bjd.19010
Ríos L, Nagore E, López JL et al. Melanoma characteristics at diagnosis from the Spanish national cutaneous melanoma registry: 15 years of experience. Actas Dermosifiliogr 2013; 104: 789-799.
Marcoval J, Moreno A, Torras A et al. Changes in incidence of malignant melanoma in the last 19 years in a tertiary hospital on the mediterranean coast. Actas Dermosifiliogr 2008; 99: 464-468.
de Vries E, Willem Coebergh J. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-2366.
Simon AE, Forbes LJL, Boniface D et al. An international measure of awareness and beliefs about cancer: development and testing of the ABC. BMJ Open 2012; 2: e001758.
Barbaric J, Sekerija M, Agius D et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer 2016; 55: 47-55.
Tejera-vaquerizo A, Mendiola-fernández M, Fernández-orland A, Herrera-ceballos E. Thick melanoma: the problem continues. J Eur Acad Dermatology Venereol 2008; 22: 575-579.
Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92: 108-118.